title: Assessment of duration of staying free from acquiring rehappening opportunistic infections among pre-ART people living with HIV/AIDS between 2008 and 2013.
abstract: Introduction. In regional state of the study area, HIV (Human Immunodeficiency Virus) prevalence is 2.2% and opportunistic infections (OIs) occurred in 88.9% of pre-ART (Antiretroviral Therapy) people living with HIV/AIDS (PLWHA). Even though OIs are prevalent in the study area, duration of staying free from acquiring rehappening opportunistic infections and its determinant factors are not studied. Method. The study was conducted in randomly selected 341 adult Pre-ART PLWHA who are included in chronic HIV care. OI free duration was estimated using the actuarial life table and Kaplan Meier survival. Cox proportional-hazard model was used to calculate hazard rate. Result. OIs were rediagnosed in three quarters (75.37%) participants. In each week the probability of getting new recurrence OI was about 15.04 per 1000 person weeks. The median duration of not acquiring OI recurrence was 54 weeks. After adjustment, variables associated with recurrence were employment status, marital status, exposure for prophylaxis and adherence to it, CD4 count, and hemoglobin value. Conclusion. Giving prophylaxis and counseling to adhere it, rise in CD4 and hemoglobin level, and enhancing job opportunities should be given for PLWHA who are on chronic HIV care while continuing the care.
authors: Department of Public Health, College of Medicine and Health Science, Debre Markos University, 269 Debre Markos, Ethiopia.
authors: Habtamu Mellie
authors: HM
authors: Bizuayehu
authors: Department of Public Health, College of Health Science, Arba Minch University, Arba Minch, Ethiopia.
authors: Direslgne Misker
authors: DM
authors: Abyu
authors: Department of Midwifery, College of Health Science, Mekelle University, Mekelle, Ethiopia.
authors: Amlaku Mulat
authors: AM
authors: Aweke
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000401:mortality* / Q000628:therapy; D000163:Acquired Immunodeficiency Syndrome / Q000401:mortality* / Q000628:therapy; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D012189:Retrospective Studies